the Prognosis of Fetoscopy Treatment of Twin Transfusion Syndrome
Launched by SHENGJING HOSPITAL · Jun 27, 2021
Trial Information
Current as of August 27, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a serious condition called twin-to-twin transfusion syndrome (TTTS) that can occur in pregnancies with twins. TTTS happens when blood circulation between the twins is uneven, which can cause health problems for both babies. The researchers want to find out how well a special treatment called fetoscopic laser surgery works for TTTS and how to better predict the outcomes for the twins after the surgery.
To participate in this study, women who are pregnant with twins and have undergone fetoscopic laser surgery for TTTS may be eligible. The study is not yet recruiting participants, so it's still in the planning stage. If you join, you can expect to help researchers gather important information that could improve future care for other women and their babies facing this condition. It’s important to note that pregnant women who choose not to participate in the study will not be included. Your involvement could make a difference in understanding and managing TTTS better.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • TTTS after fetoscopic laser surgery.
- Exclusion Criteria:
- • Pregnant women who refuse to take part in the study
About Shengjing Hospital
Shengjing Hospital, affiliated with the China Medical University, is a leading medical institution dedicated to advancing healthcare through innovative clinical research and trials. With a strong emphasis on multidisciplinary collaboration, the hospital leverages its state-of-the-art facilities and a team of experienced healthcare professionals to conduct comprehensive studies aimed at improving patient outcomes. Shengjing Hospital is committed to adhering to the highest ethical standards and regulatory guidelines, ensuring that all clinical trials are designed to enhance medical knowledge and provide safe, effective treatment options for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shenyang, Liaoning, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials